Evaluation of omalizumab therapy in pediatric patients with severe asthma
Annals of Clinical and Analytical Medicine · 01.03.2026 · 17 (3) · 214-218
DOI: 10.4328/acam.22990 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Clinical and Analytical Medicine, erschienen am 01.03.2026. Verfasst von Asena Pınar Sefer und 1 weiteren Autor:innen. Die Arbeit nennt 24 Literaturangaben.
Abstract (Originalsprache)
Aim
Severe asthma affects 2–5% of children and often remains uncontrolled despite high-dose inhaled corticosteroids (ICS) and long-acting β₂-agonists. Omalizumab, an anti-IgE monoclonal antibody, is approved for patients aged ≥ 6 years, yet evidence in younger children remains limited. This study assessed the efficacy, safety, and treatment satisfaction of omalizumab in pediatric patients aged 4–17 years with severe allergic asthma, emphasizing preschoolers.
Methods
A retrospective cohort of 21 children with GINA-defined severe asthma who received ≥ 9 months of omalizumab (May 2023–December 2024) was evaluated. Data on exacerbations, hospitalizations, systemic corticosteroid use, ICS dose, lung function (FEV₁, reversibility), and asthma control (ACT/C-ACT) were compared between baseline and month 9.
Results
Median exacerbations decreased from 8 to 2 per 6 months (p
Zitieren
APA
Sefer, A. P., & Kaya, M. Ş. (2026). Evaluation of omalizumab therapy in pediatric patients with severe asthma. Annals of Clinical and Analytical Medicine, 17(3), 214-218. https://doi.org/10.4328/acam.22990
Vancouver
Sefer AP, Kaya MŞ. Evaluation of omalizumab therapy in pediatric patients with severe asthma. Annals of Clinical and Analytical Medicine. 2026;17(3):214-218. doi:10.4328/acam.22990
BibTeX
@article{Sefer2026,
author = {Sefer, Asena Pınar and Kaya, Mehmet Şirin},
title = {Evaluation of omalizumab therapy in pediatric patients with severe asthma},
journal = {Annals of Clinical and Analytical Medicine},
year = {2026},
volume = {17},
number = {3},
pages = {214--218},
doi = {10.4328/acam.22990}
}
EUVIMED